| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 14,531 |
| Net loss | -182,779 |
| Other | 0 |
| Noncash operating lease expense | 316 |
| Prepaid expenses and other assets | 4,202 |
| Other noncurrent liabilities | 877 |
| Operating lease liabilities | -354 |
| Accrued expenses | 4,150 |
| Accounts payable | -752 |
| Change in fair value of warrant liability | -516 |
| Depreciation | 18 |
| Amortization of debt discount and accretion of deferred debt costs | 773 |
| Net accretion of discounts on investments in marketable securities | 4,224 |
| Net cash used in operating activities | -172,162 |
| Proceeds from sales and maturities of marketable securities | 212,131 |
| Purchases of property and equipment | 72 |
| Purchases of marketable securities | 326,514 |
| Net cash used in investing activities | -114,455 |
| Proceeds from issuance of common stock upon exercise of common stock warrants | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 263 |
| Proceeds from issuance of common stock upon exercise of stock options | 59 |
| Payments for taxes related to net share settlement upon vesting of restricted stock units | 1,598 |
| Payments of deferred offering costs | 0 |
| Proceeds from issuance of common stock under at-the-market program, net of issuance costs | 21,006 |
| Proceeds from issuance of common stock and pre-funded warrants in public offering, net of issuance costs | 269,903 |
| Net cash provided by financing activities | 289,633 |
| Net change in cash and cash equivalents | 3,016 |
89bio, Inc. (ETNB)
89bio, Inc. (ETNB)